Cargando…

Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide

Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral (PO) carbapenem pro-drug that is converted to the active moiety tebipenem in the enterocytes. Tebipenem has activity against multidrug-resistant Gram-negative pathogens, including extended-spectrum beta lactamase-producing Enterobacterales, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganesan, H., Gupta, V. K., Safir, M. C., Bhavnani, S. M., Talley, A. K., Melnick, D., Rubino, C. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269146/ https://www.ncbi.nlm.nih.gov/pubmed/37191505 http://dx.doi.org/10.1128/aac.01451-22

Ejemplares similares

1105. Population Pharmacokinetic Analyses for Tebipenem After the Administration of Tebipenem Pivoxil Hydrobromide
por: Ganesan, Harish, et al.
Publicado: (2021)

Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment
por: Patel, Gina, et al.
Publicado: (2022)

Bioequivalence of two oral formulations of tebipenem pivoxil hydrobromide in healthy subjects
por: Gupta, Vipul K., et al.
Publicado: (2022)

Absorption, Metabolism, and Excretion of [(14)C]-Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Male Subjects
por: Gupta, Vipul K., et al.
Publicado: (2023)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

Crystal structure of tebipenem pivoxil
por: Tang, Chao, et al.
Publicado: (2018)

Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects
por: Eckburg, Paul B., et al.
Publicado: (2019)

1122. Effect of Aluminum Hydroxide/Magnesium Hydroxide/Simethicone and Omeprazole on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects
por: Gupta, Vipul K, et al.
Publicado: (2021)

1095. Pharmacokinetics-Pharmacodynamics Evaluation of Tebipenem Pivoxil Hydrobromide Using the 10-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2021)

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Tebipenem Pivoxil Hydrobromide on QT/QTc Intervals in Healthy Subjects
por: Gupta, Vipul K., et al.
Publicado: (2021)

Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects
por: Patel, Gina, et al.
Publicado: (2023)

1120. Absorption, Metabolism, and Excretion of [(14)C]-Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects
por: Gupta, Vipul K, et al.
Publicado: (2021)

Pharmacokinetics, Urinary Excretion, and Pharmaco-Metabolomic Study of Tebipenem Pivoxil Granules After Single Escalating Oral Dose in Healthy Chinese Volunteers
por: Li, Zeyun, et al.
Publicado: (2021)

LB-3. Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study
por: Muir, Lori A, et al.
Publicado: (2020)

Investigation of pneumonia-causing pathogenic organisms in children and the usefulness of tebipenem pivoxil for their treatment
por: Kuroki, Haruo, et al.
Publicado: (2010)

Cyclodextrins as multifunctional excipients: Influence of inclusion into β-cyclodextrin on physicochemical and biological properties of tebipenem pivoxil
por: Paczkowska, Magdalena, et al.
Publicado: (2019)

The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp
por: Fernández Álvaro, Elena, et al.
Publicado: (2022)

Correction: The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp
por: Fernández Álvaro, Elena, et al.
Publicado: (2022)

Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo
por: Yao, Qi, et al.
Publicado: (2016)

Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model
por: VanScoy, B. D., et al.
Publicado: (2023)

1565. Characterization of Tebipenem (SPR859) Pharmacokinetics–Pharmacodynamics (PK-PD) for Efficacy Against Enterobacteriaceae in a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2019)

Tebipenem as an oral alternative for the treatment of typhoid caused by XDR Salmonella Typhi
por: Mylona, Elli, et al.
Publicado: (2021)

626. Tebipenem Pharmacokinetics and Soft-Tissue Distribution in Diabetic Patients with Lower Extremity Infections using In Vivo Microdialysis
por: Abouelhassan, Yasmeen, et al.
Publicado: (2022)

Stress Degradation Studies of Tebipenem and a Validated Stability-Indicating LC Method
por: Cielecka-Piontek, Judyta, et al.
Publicado: (2012)

1044. In vitro Activity of Tebipenem Against Relevant Clinical Isolates in the Presence of Pulmonary Surfactant
por: Arends, S J Ryan, et al.
Publicado: (2021)

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection
por: Negatu, Dereje A., et al.
Publicado: (2023)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2020)

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
por: Trang, M., et al.
Publicado: (2023)

1057. Tebipenem In vitro Activity Against a Collection of Pathogens Responsible for Urinary Tract Infections in the US
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

Structural insight into the inactivation of Mycobacterium tuberculosis non-classical transpeptidase Ldt(Mt2) by biapenem and tebipenem
por: Bianchet, Mario A., et al.
Publicado: (2017)

150. Low Propensity for Development of Spontaneous In Vitro Resistance to Tebipenem, Ertapenem and Meropenem Among Enterobacterales Uropathogens
por: VanScoy, Brian D, et al.
Publicado: (2022)

Tebipenem, a New Carbapenem Antibiotic, Is a Slow Substrate That Inhibits the β-Lactamase from Mycobacterium tuberculosis
por: Hazra, Saugata, et al.
Publicado: (2014)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

1041. In vitro activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections
por: Arends, S J Ryan, et al.
Publicado: (2021)

The Class A β-Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States
por: Becka, Scott A., et al.
Publicado: (2022)

1038. In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, Against a Collection of Surveillance Gram-Positive Clinical Isolates
por: Arends, S J Ryan, et al.
Publicado: (2021)

593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
por: Ganesan, Harish, et al.
Publicado: (2022)

Contemporary Evaluation of Tebipenem In Vitro Activity against Enterobacterales Clinical Isolates Causing Urinary Tract Infections in US Medical Centers (2019–2020)
por: Mendes, Rodrigo E., et al.
Publicado: (2023)

1281. An Evaluation of Tebipenem In Vitro Activity Against a Panel of Pseudomonas aeruginosa Isolates with Efflux, AmpC, and OprD Mutations
por: VanScoy, Brian D, et al.
Publicado: (2021)

1113. Oral Tebipenem as Step-Down Therapy Following Intravenous Ertapenem in a 7-day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fdgng869fk19nqlot7kmuul7df